{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024496","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.805837+00:00","generated_at":"2026-06-22T00:00:55.119006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tenaya Therapeutics Q3 net loss $30.7M; cash runway extended to mid-2024","bullets":["Cash and investments $149.5M as of Sept 30; funds expected to support operations to mid-2024.","R&D expenses $23.8M, G&A $7.5M; net loss $30.7M ($0.74 per share).","Dosing started in Phase 1 trial for TN-301 (HDAC6 inhibitor for HFpEF); data expected in 2023.","Plans to submit IND for TN-201 (MYBPC3 gene therapy for HCM) by year-end 2022; IND for TN-401 in 2023.","USPTO granted patent for TN-201 covering AAV therapy with MYBPC3; patent for TN-301 HDAC6 inhibitor allowed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024496","json":"https://secwatch.observer/filing/0000950170-22-024496.json","markdown":"https://secwatch.observer/filing/0000950170-22-024496.md","text":"https://secwatch.observer/filing/0000950170-22-024496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022024496/0000950170-22-024496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022024496/tnya-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:00:55.119006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dca1a24d9a8127ea3f2509963ce9ffb287f46758","claim":"Tenaya Therapeutics, Inc. reported third quarter ended September 30, 2022 results: net income Net loss for the second quarter ended September 30, 2022, was $30.7 million, or $0.74 per share., EPS $0.74 per share.","evidence_excerpt":"Tenaya Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022024496/0000950170-22-024496-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss for the second quarter ended September 30, 2022, was $30.7 million, or $0.74 per share."},{"label":"EPS","value":"$0.74 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}